Tweets
Price of a newly launched drug increased from $2115 per year in 2008 to $180 007 per year in 2021. In 2008 only 9% of drug cost >$150k/yr; this rose to 47% by 2021. Greater increases seen w/ biologics, rare disease and nononcology drugs https://t.co/JaGzNqCxdF
Links:
Dr. John Cush @RheumNow ( View Tweet )
4 years 1 month ago
Gout Undertreatment Persists
Despite updated gout management guidelines from EULAR and BSR, treatment of gout is suboptimal with regard to the use of urate-lowering therapy (ULT) and normalizing serum uric acid (< 6.0 mg/dl) levels.
https://t.co/qW7ZaXbnx3 https://t.co/ZBKIjuQp10
Links:
Dr. John Cush @RheumNow ( View Tweet )
4 years 1 month ago
Watch: RA Potpourri on Day One EULAR 2022: Not An Ugly Duckling
https://t.co/Lp25lP6ZZY https://t.co/wd5GCbaCLR
Links:
Dr. John Cush @RheumNow ( View Tweet )
4 years 1 month ago
Video: Residual Pain in RA
Dr. Maxime Dougados discusses OP0052 at #EULAR2022.
https://t.co/gu1Svegss8 https://t.co/G1rRizG9gW
Links:
Dr. John Cush @RheumNow ( View Tweet )
4 years 1 month ago
Review on reactive arthritis & COVID: 22 articles , 25 pts (14M:11F), age 45 yrs. Oligoarthritis was most common. Onset (COVID to arthritis) was 6-48 days. Steroids in 13, 2 w/ SSZ, Sxs improved 22/25, mean resolution was 16 +/- 57 days https://t.co/0YABcjz9Gk https://t.co/W5Vnn1NjkD
Links:
Dr. John Cush @RheumNow ( View Tweet )
4 years 1 month ago
#LB0004 #EULAR2022 Positive Phase 2 results in #lupus! Deucravacitinib, a TYK2-inhibitor reported significantly more SRI-4 response rates in DEUC vs PBO. PBO: 34.4%; DEUC 3 mg BID:58.2%, DEUC 6 mg BID:49.5%, DEUC 12 mg QD:44.9%. No major safety. Will proceed to Phase 3 @RheumNow https://t.co/cZLv6bbHer
Md Yuzaiful Md Yusof @Yuz6Yusof ( View Tweet )
4 years 1 month ago
Canadian study of 50,883 RA pts shows only 58% saw a rheumatologist yearly for 5 yrs. If >65 yrs, Rheum care assoc w/ DMARD use in 82%; but was only 31% if not under Rheum care. Worse rheum retention with age >81, male, lower SES, older Rheums https://t.co/xUxWaksgsE
Links:
Dr. John Cush @RheumNow ( View Tweet )
4 years 1 month ago
Video: Vessels Glowing in the Dark - Does it Matter?
https://t.co/ZM6kmqM9Ap https://t.co/ibqwrE3p1g
Links:
Dr. John Cush @RheumNow ( View Tweet )
4 years 1 month ago
Difficult and complicated oral ulcerations - useful algorithm and expert guideline on diagnosis and approach https://t.co/oksbEpFOAM
Dr. John Cush @RheumNow ( View Tweet )
4 years 1 month ago
FDA approved another rituximab biosimilar, rituximab-arrx (Riabni) (from Amgen), for use w/ MTX in active RA. Riabni is not currently approved for B-cell NHL, B-cell leukemia, MPA, or GPA. or pemphigus vulgaris (RTX is an orphan drug) https://t.co/Htk0xBx63X https://t.co/ep1L3YO9hl
Links:
Dr. John Cush @RheumNow ( View Tweet )
4 years 1 month ago
Watch: Major Consequences of Depression In RA
https://t.co/aVzIHDiRZ4 https://t.co/86RLXJKb64
Links:
Dr. John Cush @RheumNow ( View Tweet )
4 years 1 month ago
Watch: Cancer after Biologic Use in Patients with a History of Prior Malignancy
https://t.co/46f4xsCj31 https://t.co/rr3EfgCSCF
Links:
Dr. John Cush @RheumNow ( View Tweet )
4 years 1 month ago
